Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

1,019

Participants

Timeline

Start Date

July 16, 2015

Primary Completion Date

January 8, 2018

Study Completion Date

November 1, 2026

Conditions

Melanoma

Interventions

BIOLOGICAL

pembrolizumab

Pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle

DRUG

placebo

Normal saline solution administered IV on Day 1 of each 21-day cycle

All Listed Sponsors

collaborator

European Organisation for Research and Treatment of Cancer

UNKNOWN

lead

Merck Sharp & Dohme LLC

INDUSTRY